SCHEMBL3980944

SCHEMBL3980944

C=CCn1c(=O)c(N=O)c(N)n(CCCC)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HTT P42858 1/20 0.45
ADORA2A P29274 5/20 0.42
ADORA2B P29275 4/20 0.42
PDE4A P27815 4/20 0.42
PDE4B Q07343 4/20 0.42
PDE4C Q08493 4/20 0.42
PDE4D Q08499 4/20 0.42
MAPT P10636 3/20 0.41
PSMD14 O00487 1/20 0.41
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP3A4 P08684 1/20 0.40
CASP6 P55212 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7743865 0.87 PDE4A (0.42) ALDH1A1ADORA2AADORA2BPDE4APDE4B
SCHEMBL6571379 0.85 CYP3A4 (0.50) MEN1KMT2AALDH1A1ADORA2AADORA2B
SCHEMBL2778902 0.83 CYP3A4 (0.44) MEN1KMT2AADORA2AADORA2BPDE4A
SCHEMBL3981817 0.83 ADORA2B (0.46) MEN1KMT2AALDH1A1HTTADORA2A
SCHEMBL3979483 0.82 ADORA2B (0.45) MEN1KMT2AALDH1A1HTTADORA2A
SCHEMBL13746372 0.80 PDE4A (0.43) ALDH1A1ADORA2AADORA2BPDE4APDE4B
SCHEMBL7356240 0.78 ALDH1A1 (0.47) ALDH1A1ADORA2AADORA2BPDE4APDE4B
SCHEMBL5188473 0.77 PDE4A (0.38) ALDH1A1HTTADORA2AADORA2BPDE4A
SCHEMBL13753866 0.77 ADORA2B (0.40) ALDH1A1ADORA2AADORA2BPDE4APDE4B
SCHEMBL12311646 0.76 CYP3A4 (0.64) MEN1KMT2AALDH1A1HTTADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515972-B1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY HOFFMANN LA ROCHE (CH) 2009-05-13 EP disclosed
US-7135475-B2 Antidiabetic agents HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1515972-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-03-23 EP disclosed
US-20040014766-A1 Amide substituted xanthine derivatives HOFFMANN-LA ROCHE INC. 2004-01-22 US disclosed
WO-2003106459-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014766-A1 Amide substituted xanthine derivatives GYS2, GLS2, PYGL MEN1 2857/4885KMT2A 2893/4885ALDH1A1 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.